J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest

J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest

Source: 
Endpoints
snippet: 

A Pennsylvania federal judge on Wednesday cemented a $25 million settlement in a class action suit alleging Johnson & Johnson blocked biosimilar competition to its immunosuppressive drug Remicade.